What Is Histotripsy? A Non-Invasive Alternative for Treating Liver Tumors

Medical review: Updated July 2026. Histotripsy is an emerging technology; evidence, availability, and insurance coverage are changing.

Histotripsy is a new way to destroy selected liver tumors without an incision, needle, heat, or ionizing radiation. Instead, it uses focused ultrasound pulses to create a controlled cloud of microscopic bubbles that mechanically breaks down targeted tissue. The technology is exciting, but “non-invasive” does not mean simple, risk-free, or right for every liver tumor.

For patients searching for a non-invasive liver tumor treatment, the most important first step is a multidisciplinary review. Liver tumors include primary cancers such as hepatocellular carcinoma and metastases from other cancers. The diagnosis, number and location of tumors, liver function, disease outside the liver, prior treatment, and overall treatment goal all affect whether histotripsy should be considered.

How does histotripsy work?

The patient lies on a treatment table while a robotic arm positions an ultrasound treatment head over the liver. Diagnostic ultrasound helps the team identify the target. Very short, high-amplitude ultrasound pulses are focused at a precise point, creating acoustic cavitation—a bubble cloud that rapidly expands and collapses. Repeated pulses mechanically liquefy tissue within the planned treatment volume.

Unlike microwave or radiofrequency ablation, histotripsy is non-thermal: it does not rely on heat. Unlike stereotactic body radiation therapy, it does not use ionizing radiation. And unlike percutaneous ablation, no treatment needle is passed through the skin into the tumor. The treatment still requires anesthesia or deep sedation, specialized equipment, careful imaging, and trained physicians.

Is histotripsy FDA cleared?

In October 2023, the U.S. Food and Drug Administration granted De Novo classification for the Edison System. The indicated use is non-invasive destruction of liver tumors, including unresectable liver tumors, using a non-thermal mechanical process of focused ultrasound. This is a device indication—not a guarantee that histotripsy improves survival, is appropriate for a particular cancer, or will be covered by insurance.

The pivotal HOPE4LIVER studies enrolled a relatively small group of patients with primary or metastatic liver tumors. The trials met prespecified short-term performance goals for technical success and major complications. A one-year publication reported local-control results, but interpretation included a post hoc imaging assessment and the study did not randomize patients against surgery, thermal ablation, embolization, or radiation. These are encouraging early data, not the final word.

Who may be a candidate?

Candidacy is determined at a center with histotripsy expertise, often after review by a liver tumor board. Features that may support evaluation include:

• A confirmed primary or metastatic liver tumor that is visible and reachable with ultrasound.
• A treatment goal focused on local tumor control within a broader cancer plan.
• A tumor location where non-invasive mechanical treatment could offer an advantage.
• Ineligibility for, refusal of, or a specific reason to avoid another local treatment.
• Adequate liver function and overall health for anesthesia and follow-up.

Histotripsy may not be feasible when the ultrasound path is blocked by ribs, bowel gas, scar tissue, lung, or other anatomy; when the target cannot be adequately visualized; or when tumor size, number, location, liver function, or widespread disease makes another strategy more appropriate. A center may also apply stricter criteria than the device labeling based on experience and current evidence.

How it compares with other liver tumor treatments

The best treatment is sometimes a sequence or combination rather than a single technology. For example, systemic therapy may control disease throughout the body while a local treatment addresses one or more liver tumors. Histotripsy should be integrated into an oncology plan, not chosen from a website in isolation.

What recovery can patients expect?

Because there is no incision or needle tract into the liver, many patients can leave the hospital the same day or after a short observation period, depending on anesthesia, medical history, and center protocol. Fatigue, abdominal discomfort, nausea, or effects related to anesthesia may occur. The treatment team will provide instructions about activity, medication, hydration, and warning signs.

Recovery can be quicker than after liver surgery, but follow-up is not optional. CT or MRI is used to assess the treatment zone, and oncology follow-up evaluates the treated tumor, the rest of the liver, and disease elsewhere. Additional treatment may still be necessary.

What are the risks?

Potential risks include pain, bleeding, injury to nearby structures, liver injury or dysfunction, anesthesia-related problems, infection, incomplete treatment, and the need for another procedure. The HOPE4LIVER trials reported procedure-related major complications, even though the short-term safety performance goal was met. Novel imaging appearances can also make early follow-up interpretation challenging.

Questions worth asking include how many cases the center has performed, how the tumor board selected the treatment, what structures are near the target, how success will be measured, and what the backup plan is if the tumor is not fully treated.

Does insurance cover histotripsy?

Coverage is evolving and can vary substantially by insurer, plan, diagnosis, hospital, and treatment indication. Some patients may receive approval after prior authorization; others may face denial or an investigational-treatment policy. Medicare or commercial enrollment alone does not guarantee coverage. Ask the treating center for a written benefits review, authorization status, facility estimate, and explanation of appeal or financial-assistance options before scheduling.

How to take the next step

Ask your oncologist or liver specialist whether your case has been reviewed by a multidisciplinary liver tumor board and how histotripsy compares with resection, ablation, embolization, radiation, and systemic therapy for your specific diagnosis. If you would like help understanding image-guided treatment pathways or an appropriate referral, contact SoCal Interventional. Availability and candidacy must be confirmed directly.